Literature DB >> 12829660

Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit.

Robert F Ozols.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12829660     DOI： 10.1200/JCO.2003.03.039

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Authors:  Boris Freidlin; Richard F Little; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

Review 2.  The value of progression-free survival to patients with advanced-stage cancer.

Authors:  Lesley J Fallowfield; Anne Fleissig
Journal:  Nat Rev Clin Oncol       Date:  2011-10-18       Impact factor: 66.675

3.  The impact of perioperative packed red blood cell transfusion on survival in epithelial ovarian cancer.

Authors:  Lindsay L Morgenstern Warner; Sean C Dowdy; Janice R Martin; Maureen A Lemens; Michaela E McGree; Amy L Weaver; Karl C Podratz; Jamie N Bakkum-Gamez
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

4.  Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

Authors:  Monica Binaschi; Cecilia Simonelli; Cristina Goso; Mario Bigioni; Carlo Alberto Maggi
Journal:  Exp Ther Med       Date:  2011-01-14       Impact factor: 2.447

Review 5.  Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma.

Authors:  Jean Hoffman-Censits; Yu-Ning Wong
Journal:  Clin Genitourin Cancer       Date:  2015-03-26       Impact factor: 2.872

6.  Current status of maintenance therapy for advanced ovarian cancer.

Authors:  Joanie Mayer Hope; Stephanie V Blank
Journal:  Int J Womens Health       Date:  2010-08-09

Review 7.  Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials.

Authors:  Kristine A Donovan; Heidi S Donovan; David Cella; Martha E Gaines; Richard T Penson; Steven C Plaxe; Vivian E von Gruenigen; Deborah Watkins Bruner; Bryce B Reeve; Lari Wenzel
Journal:  J Natl Cancer Inst       Date:  2014-07-08       Impact factor: 13.506

8.  Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel.

Authors:  Stephen R Armstrong; Rashmi Narendrula; Baoqing Guo; Amadeo M Parissenti; Katherine L McCallum; Stephanie Cull; Carita Lannér
Journal:  J Ovarian Res       Date:  2012-11-30       Impact factor: 4.234

9.  Anti-Tumor Effect of Pinus massoniana Bark Proanthocyanidins on Ovarian Cancer through Induction of Cell Apoptosis and Inhibition of Cell Migration.

Authors:  Jia Liu; Jing Bai; Guoqiang Jiang; Xinli Li; Jing Wang; Dachang Wu; Lawrence Owusu; Ershao Zhang; Weiling Li
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

10.  Sensitization of ovarian carcinoma cells to Bcl-xL-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family.

Authors:  Julie Tomasina; Aurélie Malzert-Freon; Florence Giffard; Emilie Brotin; Marie-Hélène Louis; Edwige Abeilard; Sylvain Rault; Pascal Gauduchon; Laurent Poulain
Journal:  J Ovarian Res       Date:  2013-06-05       Impact factor: 4.234
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.